FastPrep-24™ Classic used in COVID-19 Vaccine Development< Back to News
MP Biomedicals FastPrep® Instruments help expedite COVID-19 current vaccine research with INOVIO Pharmaceuticals, University of Oxford and CSIRO in Australia.Jun 05, 2020
MP Biomedicals is proud to see the FastPrep-24 Classic has been instrumental in SARS-CoV-2 therapeutic research. INOVIO Pharmaceuticals, together with University of Oxford and researchers at Commonwealth Scientific and Industrial Research Organization (CSIRO) in Australia, were featured on 9 News Australia showcasing their COVID-19 vaccine development.
INOVIO’s industry leading DNA medicines are precisely designed for DNA plasmids to be delivered directly into the body’s cells through INOVIO’s proprietary smart device, CELLECTRA®. The body then produces an immune response robust enough to potentially treat or prevent disease.
MP Biomedicals supports their mission and is willing to help anyone conducting research involving SARS-CoV-2. Please contact us at [email protected] for more information.
FastPrep-24™ Classic can perform viral lysis in less than 30 seconds with high-throughput capabilities. Viral nucleic acid contents can be extracted following a cell disruption protocol of 1 or 2 runs of 20 seconds at a speed of 6.5 m/s with Lysing Matrix A and Lysing Matrix E.
MP Biomedicals remains a global leader in the automated cell lysis, cell disruption and homogenizer market with the FastPrep Instruments. The benchtop instruments provide the most advanced, rapid and thorough lysis of cells for extracting nucleic acids (DNA/RNA) and proteins. The FastPrep family of instruments includes the FastPrep-24™ 5G, FastPrep-24™ Classic, FastPrep-96™ and SuperFastPrep-2™.